search
Back to results

Pulsatile Perfusion Therapy Phase II (PPT2)

Primary Purpose

Hemorrhage

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
0 Hz Control
0.1 Hz PPT
0.05 Hz PPT
Sponsored by
Caroline Rickards
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Hemorrhage

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Aged 18 to 40 years Non-tobacco/nicotine users (e.g., cigarettes (including electronic cigarettes), chewing tobacco, nicotine gum or patches) Systolic arterial pressure <140 mmHg; diastolic arterial pressure <90 mmHg Normal 12-lead ECG (reviewed by a physician) Normal clinical results from a medical exam reviewed by a board certified physician (e.g., General Health Questionnaire - see attached document) Easily visualized internal carotid and vertebral arteries (via Doppler ultrasound) for accurate measurement of velocity and diameter. Body mass index (BMI) <30 kg/m2 unless athletic/muscular build; calculation = body weight (kg)/height (m2); this criteria is used to ensure subjects will fit inside the LBNP chamber Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions Exclusion Criteria: Age <18 or >40 years Use of tobacco/nicotine within the last 6 months (e.g., cigarettes (including electronic cigarettes), chewing tobacco, nicotine gum or patches) Body mass index (BMI) >30 kg/m2 unless athletic/muscular build; calculation = body weight (kg)/height (m2) Not abstaining from the following 24 hours prior to the experimental session: exercise, alcoholic substances, prescription or non-prescription medications (unless cleared by the medical screener), dietary supplements, herbal medications, caffeinated substances (including coffee, tea (iced or hot), caffeinated energy drinks or sodas). Inability to visualize the internal carotid and vertebral arteries (via Doppler ultrasound) for accurate measurement of velocity and diameter. Positive pregnancy test Post-menopausal females Females with an erratic/irregular menstrual cycle Use of prescription drugs, non-prescription drugs or herbal medicines known to alter cardiovascular, autonomic, or cerebrovascular function unless cleared prior to the study Use of anti-hypertensive medications Use of beta blockers Frequent use of bronchodilators (occasional use, i.e. seasonally, is allowable) Use of anti-coagulant therapy Use of non-contraceptive related hormone therapy Current or past history of hyperthyroidism, or other thyroid hormone-related disease Signs of cardiovascular abnormalities (e.g., resting systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg; abnormal 12-lead ECG) History of cerebrovascular abnormalities (e.g., prior stroke, transient ischemic attacks, epilepsy) Known history of atherosclerosis of the carotid arteries (i.e., plaque formation) History of concussion and or other loss of consciousness within the preceding month Autonomic dysfunction (e.g., Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus arrhythmia, idiopathic orthostatic hypotension, fainting disorder) Respiratory illnesses (e.g., chronic asthma (including exercise-induced asthma), Chronic Obstructive Pulmonary Disease, Reactive Airway Disease) History of anaphylaxis Known allergies to medications or other substances (e.g. latex) unless cleared prior to the study History of pre-syncopal/syncopal episodes or orthostatic hypotension Donated blood within the last 60 days History or family history of abnormal blood clotting, clots in deep veins in the legs or pelvis, or blood clots to the lungs aa) Known or suspected abdominal hernia bb) History of alcohol or drug abuse which inhibits the subject's ability to complete this study cc) Known depression, anxiety, or any other mental health issue which inhibits the subject's ability to complete this study dd) Known claustrophobia ee) Previous positive diagnosis of COVID-19

Sites / Locations

  • University of North Texas Health Science Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Pulsatile perfusion therapy (PPT)

Arm Description

Application of oscillatory lower body negative pressure (LBNP) at specific target frequencies of interest.

Outcomes

Primary Outcome Measures

Change in ScO2
Cerebral tissue oxygen saturation
Change in ICA flow
Internal carotid artery blood flow
Change in MCA velocity
Middle cerebral artery velocity
Change in circulating vasoactive mediators
Venous plasma nitric oxide and endothelin

Secondary Outcome Measures

Change in arterial pressure
Systolic, diastolic, and mean arterial pressure
Change in heart rate
Heart rate
Change in stroke volume
Stroke volume
Change in PCA velocity
Posterior cerebral artery velocity
Change in etO2 and etCO2
End-tidal oxygen and carbon dioxide

Full Information

First Posted
November 23, 2021
Last Updated
August 1, 2023
Sponsor
Caroline Rickards
search

1. Study Identification

Unique Protocol Identification Number
NCT05983744
Brief Title
Pulsatile Perfusion Therapy Phase II
Acronym
PPT2
Official Title
Pulsatile Perfusion Therapy Phase II: A Novel Approach for Improving Cerebral Tissue Blood Flow and Oxygenation
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
February 27, 2020 (Actual)
Primary Completion Date
December 17, 2021 (Actual)
Study Completion Date
December 17, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Caroline Rickards

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Individuals who suffer from a stroke, cardiac arrest, or traumatic bleeding (hemorrhage) injuries often have compromised blood flow and oxygen to the brain which can lead to the death of brain cells, and if the patient survives, subsequent difficulty in thinking and performing tasks of daily living. Traditionally, delivery of a constant flow of blood to the brain has been thought to be the most important factor for the survival of brain cells. In this study, a novel intervention will be assessed called "pulsatile perfusion therapy", delivering blood flow in a slow pulsing pattern. It is anticipated this intervention will improve brain blood flow and oxygenation during these serious clinical events. There is a specific interest in whether delivery of brain blood flow with a slow pulsatile pattern will improve oxygenation of brain tissue, particularly when the brain is challenged under low oxygen (hypoxia) and low volume (hypovolemia) conditions, simulating stroke, cardiac arrest, and hemorrhage. A technique called oscillatory lower body negative pressure (OLBNP) will be used in healthy human participants, facilitating delivery of blood flow to the brain with different pulsing patterns. This technique will allow for determination of the ideal pattern of brain blood flow that improves oxygenation of the brain tissue. Measurements will be made of substances in the blood that may be released with pulsatile flow which act on the blood vessels to increase flow and delivery of oxygen.
Detailed Description
Hemorrhage due to trauma is one of the leading causes of morbidity and mortality worldwide in both the civilian and military settings. A major factor contributing to death and disability from severe blood loss is poor tissue perfusion and oxygenation of the vital organs. Traditionally, protection of absolute cerebral blood flow (CBF) has been deemed the most important factor in maintaining perfusion and oxygenation. In recent years, it has been shown that low frequency (LF, ~0.1 Hz) pulsatile CBF is associated with increased tolerance to simulated hemorrhage in healthy human subjects, despite ≥30% reductions in absolute CBF. The underlying mechanism for this improvement in tolerance is unclear; the proposed study aims to address this knowledge gap. The central hypothesis is that LF oscillations (~0.1 Hz) will improve CBF and tissue oxygenation under hypoxic and/or hypovolemic conditions, due to increased shear stress and the release of vasoactive mediators that facilitate vasodilation and enhanced tissue perfusion. This hypothesis will be addressed in two Specific Aims under hypoxic and hypovolemic conditions: 1) determine if inducing oscillations in arterial blood pressure and CBF at 0.1 Hz elicits shear stress-induced vasodilation, subsequently increasing CBF and oxygenation; and, 2) assess the effect of 0.1 Hz oscillations on the release of shear stress-induced vasoactive mediators. Twenty human subjects (males and females) will be recruited to address these aims using oscillatory lower body negative pressure (OLBNP) to induce 0.1 Hz oscillations. Measurements will include CBF (intracranial & extracranial arteries), shear stress, cerebral oxygenation, arterial pressure, and venous blood samples for assessment of nitric oxide, prostaglandin E2, 6-keto-PGF1α (a metabolite of prostacyclin, PGI2), histamine, and endothelin-1. The rationale for the proposed research is to identify a mechanism for the previously observed increase in tolerance to simulated hemorrhage with increases in LF oscillations in arterial pressure and CBF. The approach is innovative as it challenges the traditional association of hemodynamic variability with negative clinical outcomes using a novel methodological approach in human subjects. This contribution is significant as the findings may provide an alternative approach to maintaining cerebral perfusion and oxygenation under conditions of hypovolemia and/or hypoxia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemorrhage

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
21 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pulsatile perfusion therapy (PPT)
Arm Type
Experimental
Arm Description
Application of oscillatory lower body negative pressure (LBNP) at specific target frequencies of interest.
Intervention Type
Other
Intervention Name(s)
0 Hz Control
Intervention Description
Lower body negative pressure (LBNP) applied to -60 mmHg for 10-min
Intervention Type
Other
Intervention Name(s)
0.1 Hz PPT
Intervention Description
Lower body negative pressure (LBNP) applied at a frequency of 0.1 Hz from -30 mmHg to -90 mmHg
Intervention Type
Other
Intervention Name(s)
0.05 Hz PPT
Intervention Description
Lower body negative pressure (LBNP) applied at a frequency of 0.05 Hz from -30 mmHg to -90 mmHg
Primary Outcome Measure Information:
Title
Change in ScO2
Description
Cerebral tissue oxygen saturation
Time Frame
Up to 3-months
Title
Change in ICA flow
Description
Internal carotid artery blood flow
Time Frame
Up to 3-months
Title
Change in MCA velocity
Description
Middle cerebral artery velocity
Time Frame
Up to 3-months
Title
Change in circulating vasoactive mediators
Description
Venous plasma nitric oxide and endothelin
Time Frame
Up to 3-months
Secondary Outcome Measure Information:
Title
Change in arterial pressure
Description
Systolic, diastolic, and mean arterial pressure
Time Frame
Up to 3-months
Title
Change in heart rate
Description
Heart rate
Time Frame
Up to 3-months
Title
Change in stroke volume
Description
Stroke volume
Time Frame
Up to 3-months
Title
Change in PCA velocity
Description
Posterior cerebral artery velocity
Time Frame
Up to 3-months
Title
Change in etO2 and etCO2
Description
End-tidal oxygen and carbon dioxide
Time Frame
Up to 3-months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Aged 18 to 40 years Non-tobacco/nicotine users (e.g., cigarettes (including electronic cigarettes), chewing tobacco, nicotine gum or patches) Systolic arterial pressure <140 mmHg; diastolic arterial pressure <90 mmHg Normal 12-lead ECG (reviewed by a physician) Normal clinical results from a medical exam reviewed by a board certified physician (e.g., General Health Questionnaire - see attached document) Easily visualized internal carotid and vertebral arteries (via Doppler ultrasound) for accurate measurement of velocity and diameter. Body mass index (BMI) <30 kg/m2 unless athletic/muscular build; calculation = body weight (kg)/height (m2); this criteria is used to ensure subjects will fit inside the LBNP chamber Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions Exclusion Criteria: Age <18 or >40 years Use of tobacco/nicotine within the last 6 months (e.g., cigarettes (including electronic cigarettes), chewing tobacco, nicotine gum or patches) Body mass index (BMI) >30 kg/m2 unless athletic/muscular build; calculation = body weight (kg)/height (m2) Not abstaining from the following 24 hours prior to the experimental session: exercise, alcoholic substances, prescription or non-prescription medications (unless cleared by the medical screener), dietary supplements, herbal medications, caffeinated substances (including coffee, tea (iced or hot), caffeinated energy drinks or sodas). Inability to visualize the internal carotid and vertebral arteries (via Doppler ultrasound) for accurate measurement of velocity and diameter. Positive pregnancy test Post-menopausal females Females with an erratic/irregular menstrual cycle Use of prescription drugs, non-prescription drugs or herbal medicines known to alter cardiovascular, autonomic, or cerebrovascular function unless cleared prior to the study Use of anti-hypertensive medications Use of beta blockers Frequent use of bronchodilators (occasional use, i.e. seasonally, is allowable) Use of anti-coagulant therapy Use of non-contraceptive related hormone therapy Current or past history of hyperthyroidism, or other thyroid hormone-related disease Signs of cardiovascular abnormalities (e.g., resting systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg; abnormal 12-lead ECG) History of cerebrovascular abnormalities (e.g., prior stroke, transient ischemic attacks, epilepsy) Known history of atherosclerosis of the carotid arteries (i.e., plaque formation) History of concussion and or other loss of consciousness within the preceding month Autonomic dysfunction (e.g., Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus arrhythmia, idiopathic orthostatic hypotension, fainting disorder) Respiratory illnesses (e.g., chronic asthma (including exercise-induced asthma), Chronic Obstructive Pulmonary Disease, Reactive Airway Disease) History of anaphylaxis Known allergies to medications or other substances (e.g. latex) unless cleared prior to the study History of pre-syncopal/syncopal episodes or orthostatic hypotension Donated blood within the last 60 days History or family history of abnormal blood clotting, clots in deep veins in the legs or pelvis, or blood clots to the lungs aa) Known or suspected abdominal hernia bb) History of alcohol or drug abuse which inhibits the subject's ability to complete this study cc) Known depression, anxiety, or any other mental health issue which inhibits the subject's ability to complete this study dd) Known claustrophobia ee) Previous positive diagnosis of COVID-19
Facility Information:
Facility Name
University of North Texas Health Science Center
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76107
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All IPD that underlie the results in a publication
IPD Sharing Time Frame
Starting 6 months after publication.

Learn more about this trial

Pulsatile Perfusion Therapy Phase II

We'll reach out to this number within 24 hrs